{"title":"受体 IL-17A 多态性 rs2275913 与单体脐带血移植后急性移植物抗宿主疾病有关。","authors":"Takaaki Konuma , Megumi Hamatani-Asakura , Maki Monna-Oiwa , Seiko Kato , Shohei Andoh , Kazuaki Yokoyama , Yasuhito Nannya , Satoshi Takahashi","doi":"10.1016/j.trim.2024.102096","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Interleukin-17 (IL-17) is elevated in human inflammatory and autoimmune diseases. The polymorphism in the promoter region of the <em>IL-17 A</em> gene is associated with susceptibility to several inflammatory diseases, including acute graft-versus-host disease (GVHD) following allogeneic hematopoietic cell transplantation from adult donors. However, the impacts of IL-17 A polymorphism on cord blood transplantation (CBT) outcomes remain unclear.</p></div><div><h3>Objective</h3><p>The objective of this study was to assess the impact of IL-17 A polymorphism rs2275913 on GVHD, survival, relapse, non-relapse mortality (NRM), and hematopoietic recovery after CBT.</p></div><div><h3>Study Design</h3><p>We conducted a retrospective analysis of data from adult patients who underwent single-unit CBT at our institution from January 2005 to March 2023 for whose recipient or donor DNA samples were available. IL-17 A genotyping was performed using real-time polymerase chain reaction with the TaqMan® SNP genotyping assay for rs2275913.</p></div><div><h3>Results</h3><p>A total of 158 recipients and 136 donors were evaluated in this study. Multivariate analysis showed that rs2275913 GA or AA recipients were associated with increased risk of grades II to IV acute GVHD compared to GG recipients (hazard ratio [HR], 1.46; 95% confidence interval [CI], 1.00–2.13; <em>P</em> = 0.047). Serum IL-17 A levels at eight weeks were significantly higher in rs2275913 GA or AA recipients compared to GG. The rs2275913 polymorphism did not affect survival, relapse, NRM, or hematopoietic recovery after single-unit CBT.</p></div><div><h3>Conclusion</h3><p>Our data showed recipient IL-17 A polymorphism rs2275913 was associated with the risk of grade II to IV acute GVHD in adults undergoing single-unit CBT. However, the rs2275913 polymorphism in recipients and donors did not affect survival or relapse. Thus, the polymorphism of IL-17 A rs2275913 in recipients might predict the risk of acute GVHD after single-unit CBT.</p></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"86 ","pages":"Article 102096"},"PeriodicalIF":1.6000,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0966327424001126/pdfft?md5=2be711af4f0f6c39218b6c9ce642daff&pid=1-s2.0-S0966327424001126-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Recipient IL-17A polymorphism rs2275913 is associated with acute graft-versus-host disease after single-unit cord blood transplantation\",\"authors\":\"Takaaki Konuma , Megumi Hamatani-Asakura , Maki Monna-Oiwa , Seiko Kato , Shohei Andoh , Kazuaki Yokoyama , Yasuhito Nannya , Satoshi Takahashi\",\"doi\":\"10.1016/j.trim.2024.102096\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Interleukin-17 (IL-17) is elevated in human inflammatory and autoimmune diseases. The polymorphism in the promoter region of the <em>IL-17 A</em> gene is associated with susceptibility to several inflammatory diseases, including acute graft-versus-host disease (GVHD) following allogeneic hematopoietic cell transplantation from adult donors. However, the impacts of IL-17 A polymorphism on cord blood transplantation (CBT) outcomes remain unclear.</p></div><div><h3>Objective</h3><p>The objective of this study was to assess the impact of IL-17 A polymorphism rs2275913 on GVHD, survival, relapse, non-relapse mortality (NRM), and hematopoietic recovery after CBT.</p></div><div><h3>Study Design</h3><p>We conducted a retrospective analysis of data from adult patients who underwent single-unit CBT at our institution from January 2005 to March 2023 for whose recipient or donor DNA samples were available. IL-17 A genotyping was performed using real-time polymerase chain reaction with the TaqMan® SNP genotyping assay for rs2275913.</p></div><div><h3>Results</h3><p>A total of 158 recipients and 136 donors were evaluated in this study. Multivariate analysis showed that rs2275913 GA or AA recipients were associated with increased risk of grades II to IV acute GVHD compared to GG recipients (hazard ratio [HR], 1.46; 95% confidence interval [CI], 1.00–2.13; <em>P</em> = 0.047). Serum IL-17 A levels at eight weeks were significantly higher in rs2275913 GA or AA recipients compared to GG. The rs2275913 polymorphism did not affect survival, relapse, NRM, or hematopoietic recovery after single-unit CBT.</p></div><div><h3>Conclusion</h3><p>Our data showed recipient IL-17 A polymorphism rs2275913 was associated with the risk of grade II to IV acute GVHD in adults undergoing single-unit CBT. However, the rs2275913 polymorphism in recipients and donors did not affect survival or relapse. Thus, the polymorphism of IL-17 A rs2275913 in recipients might predict the risk of acute GVHD after single-unit CBT.</p></div>\",\"PeriodicalId\":23304,\"journal\":{\"name\":\"Transplant immunology\",\"volume\":\"86 \",\"pages\":\"Article 102096\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2024-07-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S0966327424001126/pdfft?md5=2be711af4f0f6c39218b6c9ce642daff&pid=1-s2.0-S0966327424001126-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Transplant immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0966327424001126\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplant immunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0966327424001126","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景：白细胞介素-17（IL-17白细胞介素-17（IL-17）在人类炎症和自身免疫性疾病中升高。IL-17 A 基因启动子区的多态性与多种炎症性疾病的易感性有关，包括成人供者异体造血细胞移植后的急性移植物抗宿主疾病（GVHD）。然而，IL-17 A 多态性对脐带血移植（CBT）结果的影响仍不清楚：本研究旨在评估 IL-17 A 多态性 rs2275913 对 CBT 后 GVHD、存活率、复发率、非复发死亡率（NRM）和造血功能恢复的影响：我们对 2005 年 1 月至 2023 年 3 月期间在我院接受单单位 CBT 的成年患者的数据进行了回顾性分析，这些患者的受体或供体 DNA 样本均可获得。采用实时聚合酶链反应和 TaqMan® SNP 基因分型检测法对 rs2275913 进行 IL-17 A 基因分型：本研究共评估了 158 名受者和 136 名供者。多变量分析显示，与 GG 受者相比，rs2275913 GA 或 AA 受者发生 II 至 IV 级急性 GVHD 的风险增加（危险比 [HR]，1.46；95% 置信区间 [CI]，1.00-2.13；P = 0.047）。与 GG 受者相比，rs2275913 GA 或 AA 受者八周时的血清 IL-17 A 水平明显更高。rs2275913多态性不影响单组CBT后的生存、复发、NRM或造血恢复：我们的数据显示，受体 IL-17 A 多态性 rs2275913 与接受单单位 CBT 的成人发生 II 至 IV 级急性 GVHD 的风险有关。然而，受者和供者的rs2275913多态性并不影响生存或复发。因此，受者体内的IL-17 A rs2275913多态性可能会预测单单位CBT后发生急性GVHD的风险。
Recipient IL-17A polymorphism rs2275913 is associated with acute graft-versus-host disease after single-unit cord blood transplantation
Background
Interleukin-17 (IL-17) is elevated in human inflammatory and autoimmune diseases. The polymorphism in the promoter region of the IL-17 A gene is associated with susceptibility to several inflammatory diseases, including acute graft-versus-host disease (GVHD) following allogeneic hematopoietic cell transplantation from adult donors. However, the impacts of IL-17 A polymorphism on cord blood transplantation (CBT) outcomes remain unclear.
Objective
The objective of this study was to assess the impact of IL-17 A polymorphism rs2275913 on GVHD, survival, relapse, non-relapse mortality (NRM), and hematopoietic recovery after CBT.
Study Design
We conducted a retrospective analysis of data from adult patients who underwent single-unit CBT at our institution from January 2005 to March 2023 for whose recipient or donor DNA samples were available. IL-17 A genotyping was performed using real-time polymerase chain reaction with the TaqMan® SNP genotyping assay for rs2275913.
Results
A total of 158 recipients and 136 donors were evaluated in this study. Multivariate analysis showed that rs2275913 GA or AA recipients were associated with increased risk of grades II to IV acute GVHD compared to GG recipients (hazard ratio [HR], 1.46; 95% confidence interval [CI], 1.00–2.13; P = 0.047). Serum IL-17 A levels at eight weeks were significantly higher in rs2275913 GA or AA recipients compared to GG. The rs2275913 polymorphism did not affect survival, relapse, NRM, or hematopoietic recovery after single-unit CBT.
Conclusion
Our data showed recipient IL-17 A polymorphism rs2275913 was associated with the risk of grade II to IV acute GVHD in adults undergoing single-unit CBT. However, the rs2275913 polymorphism in recipients and donors did not affect survival or relapse. Thus, the polymorphism of IL-17 A rs2275913 in recipients might predict the risk of acute GVHD after single-unit CBT.
期刊介绍：
Transplant Immunology will publish up-to-date information on all aspects of the broad field it encompasses. The journal will be directed at (basic) scientists, tissue typers, transplant physicians and surgeons, and research and data on all immunological aspects of organ-, tissue- and (haematopoietic) stem cell transplantation are of potential interest to the readers of Transplant Immunology. Original papers, Review articles and Hypotheses will be considered for publication and submitted manuscripts will be rapidly peer-reviewed and published. They will be judged on the basis of scientific merit, originality, timeliness and quality.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
